Activist investor Nelson Peltz gets a taste of his own medicine

Posted on

Activist investor Nelson Peltz gets a taste of his own medicine as shareholders name for shake-up at his London-listed fund

A fund run by the activist billionaire shaking up Unilever has discovered itself within the crosshairs of its own high shareholders.

Trian Investors 1 (TI1), listed on the London Stock Exchange and managed by Nelson Peltz’s agency Trian Partners, is below siege from Invesco, Janus Henderson, Staude Capital and Pelham Capital.

The 4 funding corporations, who even have the help of Aegon Asset Management, have joined forces to name for an overhaul of TI1’s board.

In the firing line: Trian Investors 1, managed by Nelson Peltz’s agency Trian Partners, is below siege from Invesco, Janus Henderson, Staude Capital and Pelham Capital

They mentioned their goal was to realize ‘an acceptable standard of governance and to restore the trust and confidence of the independent shareholders’ in TI1.

The intervention is a blow to 79-year-old Peltz who’s within the center of an activist battle with client items big Unilever and just lately received a seat on the board, sparking hypothesis he might search to interrupt it up.

But he now faces a shareholder backlash of his own. The insurgent group was angered by a number of adjustments which TI1 made to the best way the business operated at its shareholder assembly final 12 months.

Trian was accused of having a ‘conflict of interest’ because the adjustments would improve the quantity of money it makes from managing TI1.

Shareholders wish to take away TI1’s chairman Chris Sherwell and non-executive administrators Simon Holden and Anita Rival.

They recommend funding veteran Robert Leggett, and Miles Staude of Staude Capital as replacements.

Advertisement

money/markets/article-10935697/Activist-investor-Nelson-Peltz-gets-taste-medicine.html?ns_mchannel=rss&ns_campaign=1490&ito=1490″>Source Article

Leave a Reply

Your email address will not be published.